端粒酶作为胶质母细胞瘤治疗靶点
胶质母细胞瘤是成人最常见的原发性恶性脑肿瘤,预后极差。TERT启动子突变存在于高达80%的胶质母细胞瘤样本中,是端粒酶再激活的机制之一。本文综述基因组和临床前数据,支持端粒酶作为胶质母细胞瘤的潜在「阿喀琉斯之踵」,并总结既往抗端粒酶药物经验及新方法。
要点
- TERT启动子突变存在于高达80%的胶质母细胞瘤样本中,为常见克隆性改变。
- 端粒酶再激活是肿瘤获得细胞永生的机制之一,是潜在治疗靶点。
- 基因组和临床前数据支持端粒酶作为胶质母细胞瘤的脆弱点。
核心结论
- 基因组和临床前数据支持端粒酶作为胶质母细胞瘤的潜在「阿喀琉斯之踵」。
研究设计与样本
- 综述,总结支持端粒酶作为胶质母细胞瘤治疗靶点的基因组和临床前数据,以及既往抗端粒酶药物经验和新方法。
主要发现
- TERT启动子突变首先在黑色素瘤中发现,后来发现存在于高达80%的胶质母细胞瘤样本中。
- TERT启动子突变是胶质母细胞瘤中频繁的克隆性改变。
- TERT启动子突变是端粒酶再激活的机制之一,为癌症提供细胞永生。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Glioblastoma is the most common primary malignant brain tumor in adults and it continues to have a dismal prognosis. The development of targeted therapeutics has been particularly challenging, in part due to a limited number of oncogenic mutations and significant intra-tumoral heterogeneity. TERT promoter mutations were first discovered in melanoma and later found to be present in up to 80% of glioblastoma samples. They are also frequent clonal alterations in this tumor. TERT promoter mutations are one of the mechanisms for telomerase reactivation, providing cancers with cellular immortality. Telomerase is a reverse transcriptase ribonucleoprotein complex that maintains telomere length in cells with high proliferative ability. In this article, we present genomic and pre-clinical data that support telomerase as a potential "Achilles' heel" for glioblastoma. We also summarize prior experience with anti-telomerase agents and potential new approaches to tackle this target.
引用
- Aquilanti E, Kageler L, Wen PY, et al. Telomerase as a therapeutic target in glioblastoma. Neuro Oncol. 2021. PMID: 34473298. doi:10.1093/neuonc/noab203
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。